Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

rejectedamlitelimabNegative

AI Analysis

Summary

Sanofi announced discontinuation of clinical development for amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis, and will not pursue global regulatory submissions for the program.

Outcome Details

Sanofi discontinued clinical development and decided not to submit amlitelimab for global regulatory review

Importance:5/10

Sentiment:

-0.80

drug discontinuationatopic dermatitismonoclonal antibodyregulatory decision

Related Companies

$SNY

Read the original article

Published by GlobeNewswire Pharma on July 24, 2026 5:30 AM

Read Original